MarginsXMarginsX
Home › Markets › Health Care › BBIO

BridgeBio Pharma Inc. (BBIO)

BBIO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$77.36
-1.20% on the day
Market cap
$15.1B
Large cap
Revenue · 2025
$502.1M
+126.3% on 2024
Net income · 2025
-$732.9M
-146.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1743881/000174388126000009/0001743881-26-000009-index.htm. Net income: SEC 10-K (us-gaap:ProfitLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerBBIO on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2019
SEC CIK0001743881
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$502.1M
Net income-$732.9M
Operating income-$523.4M
Net margin-146.0%
Operating margin-104.2%
Revenue growth+126.3%
Cash$570.1M
Total assets$936.0M
P/E (computed)Net income was not positive
P/S (computed)30.0×

Warning signs

Cash runway
49.9 months
$1.5B cash at September 30, 2026
Share count, 1 year
+1.1%
2025-10-21 to 2026-10-22 · +12.0% over 3 years
Going-concern doubt
No
10-Q filed October 29, 2026
Insider net buying, 12 months
-$117.8M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-10-29
Cash and burn$1.5B cash; operating cash flow -$92.2M a quarter.Report 2026-09-30
Shares outstanding194,800,782 (2026-10-22); 192,708,813 a year earlier; 173,967,052 three years earlier.Cover page 2026-10-22
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-07-24
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, San Francisco, California, United StatesPCAOB Form AP 2026-02-27
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $117.8M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$353.2M-$56.7M-$44.2M$1.5B$2.6B$945.5M10-Q 2026-10-29
Q2 2026
2026-06-30
$243.7M-$155.9M-$71.1M$677.9M$2.7B$713.1M10-Q 2026-08-10
Q1 2026
2026-03-31
$194.5M-$166.6M-$197.3M$879.9M$2.7B$580.0M10-Q 2026-05-07
Q4 2025
2025-12-31
$154.2M-$194.6M-$56.4M$570.1M$2.0B$502.1M10-K 2026-02-24
Q3 2025
2025-09-30
$120.7M-$182.7M-$109.6M$643.0M$2.0B$353.8M10-Q 2026-10-29
Q2 2025
2025-06-30
$110.6M-$183.8M-$80.7M$749.0M$0$235.8M10-Q 2026-08-10
Q1 2025
2025-03-31
$116.6M-$169.6M-$199.2M$540.6M$0$127.4M10-Q 2026-05-07
Q4 2024
2024-12-31
$5.9M-$267.4M-$195.3M$681.1M$437.3M$221.9M10-K 2026-02-24

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B72026-08-14
Latest annual report10-K2026-02-24
Latest quarterly / interim10-Q2026-10-29
Latest current report8-K2026-10-29
Latest proxyDEFA14A2026-04-24

Source: SEC EDGAR submissions feed, 834 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+5.4%
1 month+23.7%
3 months-3.6%
Year to date+2.4%
1 year+20.4%
From 52-week high-13.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
JAZZJazz Pharmaceuticals plc Common Stock (Ireland)$239.77-0.74%$15.4B
ELANElanco Animal Health Incorporated$26.41-1.38%$13.2B
ASNDAscendis Pharma A/S Ordinary Share$271.73-1.33%$17.9B
RDYDr. Reddy's Laboratories Ltd$14.70-0.27%$12.3B
BMRNBioMarin Pharmaceutical Inc.$57.99+1.33%$11.2B
ALNYAlnylam Pharmaceuticals Inc.$159.73-3.22%$21.4B
MDGLMadrigal Pharmaceuticals Inc.$423.96-0.80%$9.8B
VTRSViatris Inc.$20.74-0.38%$23.8B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier